NASDAQ:SAGE - SAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($3.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($3.41) by $0.07. The biopharmaceutical company had revenue of $3.57 million for the quarter, compared to analysts' expectations of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The business's quarterly revenue was up 35600.0% on a year-over-year basis. During the same period last year, the company posted ($2.63) earnings per share. View SAGE Therapeutics' Earnings History.

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for SAGE Therapeutics.

SAGE Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

20 brokerages have issued 12-month price objectives for SAGE Therapeutics' shares. Their forecasts range from $63.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $123.78 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

News stories about SAGE stock have trended extremely positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. SAGE Therapeutics earned a daily sentiment score of 5.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for SAGE Therapeutics.

SAGE Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totalling 7,050,000 shares, an increase of 15.6% from the December 31st total of 6,100,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 6.6 days. Currently, 13.9% of the shares of the company are short sold. View SAGE Therapeutics' Current Options Chain.

Some companies that are related to SAGE Therapeutics include GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), salesforce.com (CRM), Gilead Sciences (GILD) and GW Pharmaceuticals PLC- (GWPH).

SAGE Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Capital International Investors (7.36%), Janus Henderson Group PLC (4.66%), State Street Corp (3.20%), Victory Capital Management Inc. (2.05%) and Franklin Resources Inc. (1.69%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Alliancebernstein L.P., Franklin Resources Inc., Casdin Capital LLC, Fiera Capital Corp, New York State Common Retirement Fund, Tocqueville Asset Management L.P. and Oak Ridge Investments LLC. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

SAGE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Victory Capital Management Inc., Janus Henderson Group PLC, Boxer Capital LLC, Victory Capital Management Inc., EcoR1 Capital LLC, Capital International Investors and Zevenbergen Capital Investments LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud and Jeffrey M Jonas. View Insider Buying and Selling for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $64.45.

SAGE Therapeutics has a market capitalization of $3.34 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

The official website for SAGE Therapeutics is http://www.sagerx.com/.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]